APC
APC (Adenomatous polyposis coli protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Hepatocellular carcinoma and 5 more.
Overview
Tumour suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signalling as a negative regulator. APC activity is correlated with its phosphorylation state.
CIViC holds 5 clinical evidence items and 0 assertions across 2 variants, naming JW55, G007-LK, Nirogacestat and Regorafenib. Open Targets scores its association with cancer at 0.91 (direct and indirect evidence; datatypes genetic literature 0.79, affected pathway 0.86, literature 1.00, genetic association 0.90, somatic mutation 0.97, animal model 0.88). IntOGen calls it a driver in 43 cohorts (2 activating, 41 loss-of-function), covering Acute Myeloid Leukaemia, Anal Squamous Cell Carcinoma, Cholangiocarcinoma, Colon Adenocarcinoma, Colorectal Adenocarcinoma, Cutaneous Squamous Cell Carcinoma and others. In OnCo, 1 product record names it (Nirogacestat).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · APC (Adenomatous polyposis coli protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Hepatocellular carcinoma and 5 more.
- 1 · What it is
APC (Adenomatous polyposis coli protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Hepatocellular carcinoma and 5 more.
- 2 · What goes wrong in cancer
Tumour suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signalling as a negative regulator.
- 3 · How drugs use it
No product in this corpus aims at APC yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:583 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P25054 (protein name, function text, keywords and locations (REST API)); CIViC gene APC (5 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Colon Carcinoma, Desmoid Tumour (GraphQL API, CC0)); Open Targets ENSG00000134982 (association with cancer (MONDO_0004992) 0.91; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.56, colorectal cancer 0.86, gastric cancer 0.81, oesophageal cancer 0.55, hepatocellular carcinoma 0.74, prostate cancer 0.65 (GraphQL API, CC0)); IntOGen APC (driver in 43 cohorts (Act 2, LoF 41); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Tumour suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signalling as a negative regulator. APC activity is correlated with its phosphorylation state. Activates the GEF activity of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)-induced cell migration. Required for MMP9 up-regulation via the JNK signalling pathway in colorectal tumour cells. Location: Cell junction, adherens junction; Cytoplasm, cytoskeleton; Cell projection, lamellipodium; Cell projection, ruffle membrane (UniProt). Locus 5q22.2 (HGNC).
- Colorectal cancer: Open Targets association 0.86 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.81 with gastric cancer (MONDO_0001056); IntOGen driver in 6 cohorts (EGC, STAD, STOMACH)
- Hepatocellular carcinoma: Open Targets association 0.74 with hepatocellular carcinoma (MONDO_0007256); IntOGen driver in 2 cohorts (HCC)
- Prostate cancer: Open Targets association 0.65 with prostate cancer (MONDO_0008315); IntOGen driver in 7 cohorts (PRAD, PROSTATE)
- Oesophageal cancer: Open Targets association 0.55 with oesophageal cancer (MONDO_0007576); IntOGen driver in 4 cohorts (ESCA, ESCC)
- Biliary tract cancer: Open Targets association 0.58 with biliary tract cancer (MONDO_0003060)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 41 cohorts; CIViC holds 5 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"APC" OR ABSTRACT:"APC" OR TITLE:"APC regulator of Wnt signaling pathway" OR ABSTRACT:"APC regulator of Wnt signaling pathway" OR TITLE:"Adenomatous polyposis coli protein" OR ABSTRACT:"Adenomatous polyposis coli protein" OR TITLE:"DP2" OR ABSTRACT:"DP2" OR TITLE:"DP3" OR ABSTRACT:"DP3" OR TITLE:"DP2.5" OR ABSTRACT:"DP2.5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about APC, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetSMAD4
Shares Biliary tract cancer (all types), Colorectal cancer (KEGG map), Oesophageal cancer, CIViC.
- TargetFOXP1
Shares Biliary tract cancer (all types), Neuroendocrine tumours, Oesophageal cancer, CIViC.
- TargetMAP2K4
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, CIViC.
- TargetCDH11
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, IntOGen.
- TargetBAP1
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, CIViC.
- TargetARID2
Shares Biliary tract cancer (all types), Oesophageal cancer, Hepatocellular carcinoma, CIViC.
- TargetFGFR4
Shares Biliary tract cancer (all types), Hepatocellular carcinoma, CIViC, IntOGen.
- TargetPBRM1
Shares Biliary tract cancer (all types), Oesophageal cancer, CIViC, IntOGen.